flanders.bio is a dynamic, member driven organisation with currently more than 350 members from Belgium and abroad. We help our members to create value by organising Networking and Training Activities, supporting Internationalisation, providing Services and building Expertise. flanders.bio and its members want to be the proud advocates of a reputable global-impact ecosystem in life sciences.
News from flanders.bio and its members
Versterk ons team! flanders.bio zoekt een Manager Communicatie & Events
Ter ondersteuning van onze activiteiten en ter versterking van ons team zijn wij op zoek naar een Manager Communicatie & Events (m/v).
Ablynx - Results from the Phase III Hercules Study of Caplacizumab for the treatment of acquired TTP selected for presentation in the late-breaking abstracts session at the 2017 ASH annual meeting
Ablynx NV [Euronext Brussels and Nasdaq: ABLX] today announced that results from its Phase III HERCULES study of caplacizumab have been selected as one of only six abstracts for oral presentation in the late-breaking abstracts session at the 59th Annual Meeting of the American Society of Hematology (ASH) taking place in Atlanta, GA, on 12 December 2017.
Mithra Announces 36-month Shelf Life Extension for Tibelia®
Mithra (Euronext Brussels: MITRA), a company specialized in Women’s Health, today confirms the extended shelf-life of 36 months of its complex therapeutic product Tibelia®, as compared to 24 months for other currently available tibolone-based products.
Galapagos initiates Phase 1 study with novel CF corrector GLPG3221
Galapagos NV (Euronext & NASDAQ: GLPG) announces initiation of a Phase 1 study with a novel C2 corrector GLPG3221 for cystic fibrosis (CF). Galapagos receives a $10 million milestone payment from its collaboration partner AbbVie for this achievement.
Promethera Biosciences Provides Update on Executive Management Team
Promethera Biosciences SA, a global innovator in cell-based medicines and liver diseases, today announced the promotion of Mark Johnston to Chief Commercial Officer of Promethera Biosciences group (Belgium) and Managing Director of Promethera Biosciences LLC (USA); and Jef Pinxteren, Ph.D., to Vice President Operations of Promethera Biosciences group, effective immediately. Both have more than 20 years of experience in the field of cell therapy.